Why the study?
The association between coronary physiological progression and clinical outcomes had not been investigated.
Does total physiological atherosclerotic burden and its progression (assessed by 3V-QFR and △3V-QFR) predict MACE in patients with coronary artery disease?
Cohort (n=421)
Does total physiological atherosclerotic burden and its progression (assessed by 3V-QFR and △3V-QFR) predict MACE in patients with coronary artery disease?
Total physiological atherosclerotic burden and its progression assessed by serial 3V-QFR provide incremental prognostic value for predicting MACE in patients with coronary artery disease.
May support serial 3V-QFR for MACE risk stratification in CAD; hypothesis-generating and requires prospective validation.
The association between coronary physiological progression and clinical outcomes has not been investigated. A total of 421 patients who underwent serial coronary angiography at least 6 months apart were included. Total physiological atherosclerotic burden was characterized by sum of quantitative flow ratio in 3 epicardial vessels (3V-QFR). The relationships of the 3V-QFR and its longitudinal change (△3V-QFR) with major adverse cardiovascular events (MACE) were explored. 3V-QFR values derived from follow-up angiograms were slightly lower compared with baseline (2.85 [2.77, 2.90] vs 2.86 [2.80, 2.90], P < .001). The median △3V-QFR value was −0.01 (−0.05, 0.02). The multivariable models demonstrated that follow-up 3V-QFR and △3V-QFR were independently associated with MACE (both P < .05). Patients with both low follow-up 3V-QFR (≤2.78) and low △3V-QFR (≤−0.05) presented 3 times higher risk of MACE than those without (hazard ratio: 2.953, 95% confidence interval 1.428–6.104, P = .003). Furthermore, adding patient-level 3V-QFR and △3V-QFR to clinical model significantly improved the predictability for MACE. In conclusion, total physiological atherosclerotic burden and its progression can provide incremental prognostic value over clinical characteristics, supporting the use of coronary physiology in the evaluation of disease progression and for the identification of vulnerable patients.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2023) conducted a cohort in Coronary Artery Disease (n=421). Low follow-up 3V-QFR (≤2.78) and low △3V-QFR (≤−0.05) vs. Patients without both low follow-up 3V-QFR and low △3V-QFR was evaluated on Major adverse cardiovascular events (MACE) (HR 2.953, 95% CI 1.428-6.104, p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: